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IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer
activity has been reported recently in AIDS-related Kaposi’s sarcoma, a tumour of endothelial cell origin. The high vascularity and
responsiveness to immunotherapy of renal cell carcinoma (RCC) makes such a tumour a potential target for IM862. In all, 25 patients
were accrued in a prospective phase II trial using a standard two-step design. The main inclusion criteria were WHO performance
status p2, age over 18 years, expected survival 43 months, normal marrow, kidney and liver functions. IM862 was given intranasally
at a dose of 20mg three times daily. Each cycle consisted of 8 consecutive weeks of treatment. All 25 patients were fully evaluable for
response and 24 for toxicities. Median age was 62 years (range 42–76), median WHO PS was 1 (0–2). No grade 2 or 3 toxicities
related to the study drug have been recorded. Eight patients had stable disease (SD) and 17 progressed while on treatment. Median
survival was 7.9 months (range 2.7–20). Median time to progression was 1.9 months (range 1.2–12.6). Median duration of SD was 6
months (range 5.2–12.6þ). Analysis of blood angiogenic markers showed a significant decrease of plasma vascular endothelial
growth factor (VEGF) levels after 4 and 8 weeks of therapy. Treatment with IM862 has no toxicity, but does not lead to any significant
objective responses in metastatic RCC. IM862 should not be further evaluated as a single agent at these doses and schedule for this
population of patients. The decrease in VEGF levels warrants further investigation of IM862 as an antiangiogenic therapy.
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Renal cell carcinoma (RCC) is resistant to most chemotherapeutic
agents (Godley and Ataga, 2000). Although immunotherapy with
interleukin-2 (IL-2), interferon a (IFNa) or both is being
considered standard, objective responses are seen only in 10–
20% of patients (Bukowski, 1997; Fossa, 2000). Therefore, the
identification of new potentially effective agents is of high priority
for clinical investigation (Berg et al, 2000).
IM862 is a naturally occurring dipeptide (L-glu-L-trp) whose
exact mechanisms of action are currently unknown. In animal
experiments, dose-dependent increase in natural killer (NK) cells
has been observed, together with activation of lymphocytes T4 and
T8 and polarisation to the Th1 profile. IM862 has also been shown
to be a potent antiangiogenic agent both in vitro and in vivo
(IM862 Investigator’s Brochure, 1998; Ferrario et al, 2000). A
significant anticancer activity has been reported recently in AIDS-
related Kaposi’s sarcoma, a tumour of endothelial cell origin
(Tulpule et al, 2000). Responses have also been documented in
ovarian carcinoma and skin melanoma (Garcia et al, 2001).
Owing to the vascular nature of renal tumours, an antiangio-
genic approach is attractive. Furthermore, the responsiveness of
RCC to immune therapy makes it a potential target for the
antiangiogenic and immunomodulatory agent IM862. We thus
initiated a phase II study of IM862 in patients with metastatic RCC
using a three times daily nasal administration. We confirm the lack
of significant toxicity of this drug. Blood samples were prospec-
tively collected throughout the study to analyse surrogate markers
of angiogenesis. We did not observe any objective response,
although there were effects on plasma vascular endothelial growth
factor (VEGF).
PATIENTS AND METHODS
Patients selection
Patients were required to have cytologically and/or histologically
proven metastatic RCC, a World Health Organization (WHO)
performance status of 0–2, to be over 18 years of age, to have an
expected survival of at least 3 months and no history of other
invasive cancer. There were no exclusions for prior therapy, but at
least 3 weeks had to have elapsed since the last dose of the prior
drug or radiotherapy. Patients were also required to have adequate
bone marrow, kidney and liver function defined by serum
creatinine p170mmoll
 1, AST/ALT p3 times the upper limit of
normal (ULN), total bilirubin o2 times the ULN, haemoglobin
X10gdl
 1, WBC X3.10
9l
 1, ANC X2.10
9l
 1 and platelet count
X100 10
9l
 1. The study was approved by the Central Oxford
Research Ethic Committee (COREC) and conducted according to
the recommendations of the Declaration of Helsinki and the
Association of British Pharmaceutical Industry guidelines for
Good Clinical Practice. All patients provided written informed
Received 27 April 2004; revised 21 July 2004; accepted 22 July 2004;
published online 19 October 2004
*Correspondence: Dr AL Harris; E-mail: aharris.lab@cancer.org.uk
2Current address: Fondation-Ho ˆpital Saint Joseph, De ´partement d’On-
cologie, 185 rue Raymond Losserand, 75014 Paris, France
British Journal of Cancer (2004) 91, 1645–1650
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
lconsent prior to study entry. In all, 25 patients were enrolled in the
Cancer Research UK Medical Oncology Unit of Oxford.
Treatment and dose modifications
IM862 was administered intranasally at a dose of 20mg three times
daily throughout the duration of treatment. Each cycle of
treatment consisted of 8 weeks of therapy. With the exception of
haematological toxicity, any grade 4 toxicity attributable to the
study drug led to definitive cessation of treatment. Any grade 3
toxicity led to temporary discontinuation of the study drug and
treatment was to be resumed at full dose when toxicity resolved to
grade 1. Reoccurrence of the same grade 3 event after rechallenge
or unresolved toxicity led to withdrawal from the study.
Patient follow-up and study end points
The primary end point for this study was objective tumour
response rate or sustained disease stabilisation. Response evalua-
tions were performed after an initial 8 weeks of therapy and every
8 weeks thereafter. Earlier evaluations were performed in patients
who experienced clinical signs or symptoms suggesting disease
progression. Responses were defined according to standard WHO
criteria. A complete response (CR) required the complete
disappearance of all objective evidence of disease as measured
on two separate occasions no less than 4 weeks apart. A partial
response (PR) was defined as a more than 50% reduction in
the sum of the products of the perpendicular diameters of
bidimensional target lesions without any progression of other
lesions by more than 25% or appearance of any new lesion.
Progressive disease (PD) was defined as the enlargement of any
known measurable lesion by more than 25% or the development
of any new metastatic lesion. When the criteria for PR or PD
were not fulfilled, patients were classified as having stable disease
(SD). Toxicity grading was by the NCI common toxicity
criteria version 2.0. Toxicity evaluations were performed at 2
and 4 weeks and then every 4 weeks thereafter. Compliance
with study medication was documented by interview, returned
medication and completion of a patient’s diary. Time to
progression was calculated from the onset of treatment to the
date of first documented disease progression or relapse.
Overall survival was calculated from the onset of treatment to
the date of death or time to loss of follow-up. Whenever data were
censored, estimates were calculated by using the Kaplan–Meier
product-limit method. A secondary objective of this study was to
assess the role of urine, serum and plasma markers to monitor an
antiangiogenic effect.
Measurement of angiogenic markers
Blood samples were collected prior to the first administration of
IM862 and on weeks 2, 4 and 8 and every 8 weeks subsequently.
The following markers were assessed: serum and plasma VEGF
levels, serum vascular cell adhesion molecule-1 (VCAM-1), E-
selectine (E-Sel), von Willebrand’s factor antigen (vWF) and
inhibitor of urokinase plasminogen activator (PAI-1). The 10-ml
blood sample was chilled on ice, centrifuged at 2000r.p.m. for
10min at 41C and stored in 1.5-ml aliquots at  701C until analysis.
Serum VCAM-1, E-selectin and serum/plasma VEGF were
measured using ELISA kits supplied by R&D systems (Abingdon,
UK). The serum vWF was measured using ELISA kits from
American Diagnostica (Greenwich, Connecticut, USA) and a
standard vWF from the National Institute for Biological Standards
and Controls (Potters Bar, Hertfordshire, UK). Plasma PAI-1 was
analysed by ELISA using in-house methods as described pre-
viously (Stephens et al, 1997). The normal range (or mean7s.d.)
for each assay was as published previously: serum VEGF 62–
707pgml
 1 (mean 220pgml
 1); plasma VEGF 9–109pgml
 1;
plasma PAI-1 8.3–17Uml
 1; serum VCAM-1 5257173ngml
 1;
serum E-selectin 48.37719.6ngml
 1; serum vWF 103730IUdl
 1
(Stephens et al, 1997; Braybrooke et al, 2000). Analysis of the
angiogenic markers was made in comparison with a healthy
control population without cancer (n¼39) recruited among
asymptomatic hospital workers, age and sex matched for the
cases. Exclusion criteria for all control subjects were malignancy,
acute or chronic liver and kidney diseases, connective tissue
disease, psoriasis, scleroderma, diabetes and symptomatic vascular
diseases.
Statistical considerations
Patient accrual was performed according to a standard two-step
design. An initial 14 patients were accrued, with at least one
response or alternatively three SD needing to be observed in order
to proceed to the second accrual stage with an additional 11
patients. The treatment would be considered worth of further
study if two or more of 25 patients experienced an objective
response. This design yields a 0.95 or greater probability of
accepting the regime if the true response rate is at least 20%, and a
0.69 or greater probability of rejecting the regime if the true
response rate is less than 5%. Demographic and baseline
characteristics were summarised by descriptive statistics. Efficacy
and safety parameters were evaluated in all enrolled subjects.
Confidence intervals on response rates were computed using the
binomial distribution. The Wilcoxon rank-sum test was used to
analyse differences in angiogenic markers before and after 4 and 8
weeks of therapy and Student’s t-test to compare pretreatment
angiogenic marker levels with control values. The analysis was
performed using the Stata statistical software, release 5.0 package
(Stata Corp., College Station, TX, USA).
RESULTS
Patient characteristics
The demographic data, sites of metastatic disease and previous
therapies are summarised in Table 1. The median age was 62 years
(range 42–76) and the median WHO performance status was 1
(range 0–2). Except for six patients, who had lymph nodes
metastases only, all patients had visceral metastatic involvement
with a median number of metastatic sites of 2 (range 1–4). The
median interval from initial diagnosis to first relapse was 3.7
months (range 0–122 months). In all, 11 patients presented with
synchronous metastatic disease at the time of initial diagnosis.
Two patients had received prior immunotherapy with IFNa, six
had received prior antiangiogenic agent (razoxane 1, bryostatin 3
and marimastat 2), one had received a retinoid (tazarotene), four
had received medroxyprogesterone acetate, 15 had underwent
radical nephrectomy. In total, 14 patients were treated in a first-
line metastatic setting, nine patients were treated in second line
and two in third line. A total of 52 cycles of study treatment were
administered to the 25 patients. The median number of treatment
cycles was 2 (range 1–6), and the median duration of follow-up at
the time of this analysis was 7 months (range 3–20 months).
Tumour response and survival
In all, 25 patients were assessable for response. No objective
response was observed. Eight patients (32%; 95% CI: 15–53%) had
SD, of which three occurred in the first cohort of 14 patients,
leading to the extension of the accrual to 25 patients according to
the study design. Median duration of SD was 6 months (range 5.2–
12.6þ). Of note, SDs were observed only in patients with
previously documented slowly progressing disease. All patients
with synchronous metastatic disease treated in first-line therapy
progressed while on the study drug. With a median follow-up
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lduration of 7 months, 14 of all 25 patients have died of disease
progression. Only one patient remains on study drug on a
compassionate basis at 12.6þ months. The median time to
progression was 1.9 months (range 1.2–12.6þ months). The
median overall survival was 7.9 months (range 2.7–20 months)
(Figure 1).
Toxicity
A total of 24 patients, who received a total of 52 cycles (415 weeks
of treatment), were assessable for toxicity. One patient included
with a baseline performance status of 2 went off study prematurely
after 1 week because of a significant deterioration of health, and
assessment of toxicity was therefore not available. Side effects
associated with treatment are listed in Table 2. Although several
grade 3 toxicities were reported, none were related to the study
drug in the investigators’ opinion. The only concern was for a
patient with known ulcerative colitis, who experienced a flare of
his digestive symptoms while on treatment. The drug was
discontinued and symptoms resolved, but after treatment with
IM862 was resumed his symptoms exacerbated again, leading to
definitive cessation of the drug and the patient went off study.
Relationship of this event to the study drug could not be
ascertained, but was felt to be possibly related. Overall, treatment
was discontinued prematurely because of toxicity concern for this
patient only. For all other cases, no treatment delay nor dose
reduction were necessary. Toxicities probably related to the study
drug included two episodes of, respectively, grade 1 and 2 sinusitis
and four patients experiencing grade 1 headache.
Analysis of angiogenic markers
The results for the plasma/serum surrogate markers of angiogen-
esis are summarised in Table 3. Blood samples from only 23
patients were fully available at week 8 to allow for meaningful
analysis and comparison between baseline and controls at 4 or 8
weeks of therapy. As compared to a healthy control group, we
found at baseline, prior to therapy, significantly elevated levels of
serum and plasma VEGF, serum VCAM-1 and vWF and plasma
Table 1 Patients characteristics and previous therapies
Number of patients 25
Sex (M/F) 17/8
Age (in years)
Median 62
Range 42–76
Performance status (WHO)
Median 1
0 9 (36%)
1 11 (44%)
2 5 (20%)
Number of metastatic sites
Median 1
11 4
29
X32
Dominant metastatic site
Visceral 19 (76%)
Lung only 7 (28%)
Liver (7 other sites) 5 (20%)
Other 6 (24%)
Bones (7 other sites) 4 (16%)
Lymph nodes only 6 (24%)
Prior nephrectomy 15 (60%)
Prior therapy for metastatic disease
Immunotherapy 2 (8%)
Antiangiogenic agent 6 (24%)
Medroxyprogesterone acetate (MPA) 4 (16%)
Retinoid (tazarotene) 1 (4%)
Radiotherapy 8 (32%)
Disease-free interval
a (months)
Median 3.7
Range 0–122.2
Nb metastatic at presentation 11
Laboratory studies: median (range)
Haemoglobin (gdl
 1) 12 (9–16)
LDH (IUl
 1) 173 (110–397; ULN: 250)
Alkaline phosphatase (IUl
 1) 219 (130–1116; ULN: 250)
Creatinine (mmoll
 1) 105 (71–188; ULN: 150)
aTime from initial diagnosis to first disease relapse; ULN¼upper limit of normal;
LDH¼lactate dehydrogenase.
Time to progression, N = 25
0
0.25
0.5
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1
0
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Overall survival, N = 25
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B
Figure 1 Kaplan–Meier estimates of (A) time to progression and (B)
overall survival for all enrolled patients (n¼25).
Table 2 Worst toxicity grade per patient (n¼24) across all 52 cycles
Toxicity grade
Toxicity 0 1 2 3 4
Fatigue/asthenia 4 9 6 5 —
Headache 20 4 — — —
Pain 13 7 3 1 —
Anorexia 23 1 — — —
Nausea 13 4 5 2 —
Vomiting 16 4 1 3 —
Sinusitis 22 1 1 — —
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lPAI-1 for renal cell cancer patients (serum VEGF, P¼0.0004,
rank-sum test; plasma VEGF, P¼0.0003, Mann–Whitney test;
serum VCAM-1, P¼0.0082, Student’s t-test; serum vWF,
P¼0.0018, Student’s t-test; plasma PAI-1, P¼0.0040, Student’s
t-test). After 4 and 8 weeks on therapy, the only effect was seen on
the levels of plasma VEGF, with a significant decrease from
280pgml
 1 prior to therapy to 200pgml
 1 at week 4 (P¼0.02,
signrank test) and 120pgml
 1 at week 8 (P¼0.0065, signrank
test). Therefore, the levels of plasma VEGF seemed to decrease
with duration of treatment. Whatever the angiogenic marker
considered, there was no significant difference between stable
and progressing patients in the levels of any marker, whether
at baseline or after 4 or 8 weeks on therapy (Table 4). For
example, the decrease in plasma VEGF levels between baseline
and week 8 was, respectively, 300 vs 210 for SD and 210 vs
100pgml
 1 for PD.
DISCUSSION
Since the first reports in the mid-80s of effective immuno-
therapy with IFNa and subsequently IL-2 for metastatic RCC, little
progress has been really made and response rates are still
plateauing around 15% in large multicentre trials (Hernberg et al,
1999). There is therefore an urgent need for identification of new
effective agents and especially those representing novel paradigms
such as targeting of tumour angiogenesis. The rationale for using
IM862 was its known immunomodulatory and antiangio-
genic properties, making this compound a good candidate for
treatment of a highly vascularised tumour responsive to immuno-
therapy. Furthermore, a demonstrated activity of IM862 in AIDS-
related Kaposi’s sarcoma (Tulpule et al, 2000) together with
minimal toxicity, especially with regard to the many side
effects encountered with IL-2 and IFNa, prompted us to initiate
this phase II trial.
We were able to confirm, like others (Tulpule et al, 2000; Garcia
et al, 2001), the lack of significant toxicity of IM862. We did not
observe any objective response. Moreover, the design of our trial
allowed for SD (no change for at least 8 weeks) to account as a
clinical benefit, and the observation of three SDs at 8 weeks in the
first part of the study led to extension of accrual to 25 patients.
Despite this, a careful review of definitive results showed that SD
had been observed only in pretreated patients and not in patients
with synchronous metastatic disease. This could mean that the
recorded SD might only reflect the natural history of a slowly
progressing disease.
Many hypotheses could account for a lack of effectiveness of
IM862 towards RCC in our study. First, the dosing and schedule
used could be inadequate and we had no way to evaluate if
therapeutically active concentrations of IM862 had been reached,
such as by measuring IM862 blood levels or modulation of Th1
lymphocyte subset. However, Tulpule et al (2000) used a lower
dose of 5mg given intranasally once daily every other day or for 5
days, followed by 5 days of rest. For this lower concentration, a
demonstrable clinical effect was recorded in terms of response
rate. The optimal dose for treatment of solid tumour remains to be
determined. Second, RCC could represent a naturally resistant
tumour to antiangiogenic treatment. This seems unlikely, as in
theory tumour blood vessels are genetically stable and therefore
should not exhibit any resistance to an effective antiangiogenic
therapy. In addition, several other antiangiogenic compounds such
as razoxane, bryostatin-1, TNP-470, or anti-VEGF antibodies have
shown some activity with even objective tumour responses in RCC
(Stadler et al, 1999; Braybrooke et al, 2000; Pagliaro et al, 2000;
Yang et al, 2003). Third, the primary end point, objective response
rate, could be inadequate to assess the efficacy of an antiangiogenic
agent which is in theory thought to be more cytostatic than
cytotoxic. A surrogate end point could have been, for example,
time to progression, such as in the pivotal randomised phase II
study recently reported by Yang et al (2003), which showed some
benefit of bevacizumab in metastatic RCC. However, at the time
when this study was originally designed, this was not a commonly
accepted end point. Moreover, in this randomised phase II study,
only the high-dose bevacizumab arm showed a significant effect
over placebo and was associated with a 10% ORR. Similarly, the
effectiveness of bevacizumab in combination with chemotherapy
Table 3 Summary of changes in plasma/serum markers of angiogenesis
Baseline
Marker Controls (n¼39) Patients (n¼23) Week 4 Week 8
Serum VEGF (pgml
 1) 20 (1199.3) 185 (218.552)* 170 (60.600) 180 (213.326)
Plasma VEGF (pgml
 1) 70 (221.024) 280 (555.927)* 200 (486.197)** 120 (177.708)**
Serum VCAM-1 (ngml
 1) 460 (133.83) 640 (165.6)* 620 (182.6) 645 (256.3)
Serum E-selectin (ngml
 1) 42 (18.37) 43.5 (19.6) 43 (19.2) 44 (25.2)
Serum vWF (IUdl
 1) 103 (21.82) 138 (26.9)* 138 (29.6) 146 (27.9)
Plasma PAI-1 (mgl
 1) 7.1 (5.1) 16.5 (10.5)* 15 (12.7) 14 (11.7)
Median values (standard deviation). *Significantly increased (Po0.05). **Significant decrease (Po0.05).
Table 4 Comparison of plasma/serum markers of angiogenesis between patients with stable or progressive disease
Baseline (n¼23) Week 8 (n¼23) P
Marker Stable disease Progressive disease Stable disease Progressive disease Baseline 8 weeks
Serum VEGF (pgml
 1) 200 (100.162) 180 (276.462) 165 (86.848) 180 (276.458) NS* NS*
Plasma VEGF (pgml
 1) 300 (550.492) 210 (578.123) 210 (409.944) 100 (575.927) NS* NS*
Serum VCAM-1 (ngml
 1) 660 (151) 600 (175) 650 (263) 610 (258) NS** NS**
Serum E-selectin (ngml
 1) 42 (14) 46 (23) 46 (29) 44 (23) NS** NS**
Serum vWF (IUdl
 1) 128 (34.6) 144.5 (19.8) 148.5 (32.8) 146 (25) NS** NS*
Plasma uPAsr (mgl
 1) 20 (11) 14.3 (9.7) 15.6 (13.8) 13 (9.4) NS** NS**
Median values (standard deviation). *Values calculated by ranksum test. **Values calculated by Student’s t-test. NS¼not significant (P40.05).
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lfor metastatic colon cancer was seen with a better response rate,
time to progression and overall survival as compared to
chemotherapy alone (Hurwitz et al, 2004). Therefore, to achieve
an objective response with an antiangiogenic compound does
not seem unrealistic, and the fact that Tulpule et al (2000)
reported objective responses in Kaposi’s sarcoma with IM862
initially prompted us to choose response rate as the primary
objective in our study. But, as already mentioned earlier, we
allowed for SD to account as a clinical benefit in the design of our
trial, thus anticipating a potential effect other than tumour
shrinkage.
The median time to progression and overall survival of,
respectively, 1.9 and 7.9 months are similar to those reported
earlier in the same institution for a larger phase II study involving
another antiangiogenic drug (Braybrooke et al, 2000). Moreover,
despite the lack of effectiveness in term of response rate, the
observed median overall survival is similar to the one reported in
the MRC phase III randomised trial, comparing IFNa (8.5 months)
to medroxyprogesterone acetate, with obviously a toxicity profile
that would favour IM862 (MRC Renal Cancer Collaborators, 1999).
Therefore, even if no responses were observed, one cannot
completely rule out some activity of IM862 in term of prolongation
of SD or time to progression, as it has been recently
reported for bevacizumab (Yang et al, 2003). The answer to such
a question would only be clarified in a larger randomised, placebo-
controlled trial.
The evaluation of serum and plasma markers of angiogenesis
may have a role to play in assessing the efficacy of novel
antiangiogenic drugs (Harris, 1997; Deplanque and Harris, 2000).
Elevated levels of serum VEGF, E-selectin and VCAM-1, and of
plasma PAI-1 and VEGF, have already been linked to a worse
prognosis in a variety of cancers (Kuroi and Toi, 2001). In a
previous study, we were able to find a significant difference in
the levels of serum VCAM-1 between patients with PD compared
to those with SD (Braybrooke et al, 2000). This was not the
case in the present study, maybe due to the smaller number of
patients or the different antiangiogenic agent used. Similarly, we
could not find any difference in the levels of the other angiogenic
markers between patients with PD and SD. However, a signifi-
cant decline of plasma VEGF levels was observed after 4 and 8
weeks of therapy for all patients as compared to pretreatment
levels. This significant decline in plasma VEGF levels would
make IM862 an antiangiogenic agent worth of consideration for
further investigation. Effectively, some preliminary studies
have linked VEGF levels with tumour burden in colon carcinoma
(Nakayama et al, 2002; De Vita et al, 2004). Interestingly,
VEGF levels dropped significantly after surgery and persistent
elevated VEGF levels correlated with relapse, indicating signi-
ficant residual disease. If lowering of VEGF levels by IM862
could be further confirmed in other studies, this could form
the basis for designing clinical trials in other settings such as
minimal residual disease after tumour debulking, that is, in an
adjuvant setting. Moreover, the apparent lack of significant
toxicity of IM862 would make it an attractive candidate for
combination with other chemotherapy or biologic agents.
Indeed, combination of an antiangiogenic agent with low-dose
chemotherapy is highly synergistic in preclinical models (Klement
et al, 2000).
In conclusion, IM862 has no activity as a single agent against
RCC, at least with the dosing and schedule used in our study and if
response rate is considered a primary end point. However, because
of its lack of toxicity and preliminary data showing some activity
in other types of cancer, combination of IM862 with other drugs
such as chemotherapy or biologic agents could be worth
considering, especially if a biological effect such as the decrease
of VEGF levels could be confirmed.
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